Reproductive Hormone Market
                     Reproductive Hormone Market- Size, Share, Outlook, and Opportunity 
Analysis, 2020- 2027
Artificially produced reproductive hormones are used for various medical 
reproductive conditions. There are few brands available in market which 
includes, Cenestin, Ogen, Femtrace, Menest (Pro), and Divigel. The reproductive
hormones play major role in fertility and sexuality. In females, estrogen and 
progesterone are two important hormones that help them to manage their sex 
characteristics and play functional role in menstrual cycle, fertility, and pregnancy.
Similarly, in males, testosterone is an important hormone that help men to 
develop sperm in the testes.
Request  a  sample  copy  of  this  report:-  https://www.coherentmarketinsights.com/insight/request-
sample/3185 
The artificial production of such hormones is done by two methods, which include
source analogue and recombinant hormones. In source analogue, the source of
hormone is accessible easily, for example, the LH like analogue is urinary hCG.
The LH preparation is extracted from the urine of pregnant women. The variation
in  such  hormone  may  differ  in  batch-to-batch  as  per  variation  in  bioactivity.
Similarly, recombinant hormones are produced from transfected Chinese hamster
ovary cells and purified by using immunoaffinity chromatography technique.
The reproductive hormone market size is expected to increase over the forecast
period, owing to rising drug approvals of reproductive hormones. For instance, in
2018,  TherapeuticsMD  Inc.  received  the  U.S.  FDA approval  for  its  BIJUVA
(Estradiol  and Progesterone)  Capsules  for  treatment  of  vasomotor  symptoms
associated with menopause.
Furthermore,  increasing  number  of  infertility  in  women  is  expected  to  drive
growth of this market. For instance, in 2010, according to WHO, there were 48.5
million infertile couples, globally. Additionally, according to a survey conducted by
Centers  for  Disease  Control  and  Prevention,  in  between  2006-2010,  1  in  8
couples had faced problems of sustaining pregnancy in the U.S. Therefore, such
increasing burden of infertility across the globe, is expected to drive growth of the
reproductive hormone market.
Increasing drugs recalls is a major factor responsible for restraining growth of the
reproductive  hormone market.  For  instance,  in  2017,  Medisca Inc.  voluntarily
issued recalls for its range of hormone drugs including ESTRADIOL, USP Bulk
(Hemihydrate),  ESTRADIOL,  ESTRONE,  USP  Bulk,  and  ESTRIOL,  USP
(Micronized) Bulk, due to lack of standard good manufacturing practices which
was noted by U.S. FDA inspection.
On  the  basis  of  region,  North  America  is  expected  to  be  dominant  in  the
reproductive hormone market  in  forecasted periods,  owing to increasing drug
approval  and  launches  of  reproductive  hormones  in  the  U.S.  For  instance,
AbbVie Inc.  received U.S. FDA approval  for  ORILISSA (elagolix)  drug for the
treatment of moderate-to-severe pain associated with endometriosis. Similarly, in
January  2019,  Ferring  Pharmaceuticals  acquired  the  U.S.  commercialization
rights  of  Ganirelix  Acetate  Injection  from  Sun  Pharmaceutical  Industries  Ltd.
through addition of Ganirelix drug into its product portfolio. Through this strategy,
Ferring Pharmaceuticals expanded its reproductive medicine portfolio offerings in
the U.S. market.      
Asia Pacific is expected to be the highest growing region in the reproductive
hormone market over the forecast period. For instance, as per The Economist
Intelligence Unit Limited 2019 report, the fertility rate of Southeast Asia fell from
5.5 to 2.4 in between 1970 to 2015. By 2030, it is projected to fall down to 2.1,
which  is  attributed  to  decreasing  fertility  rate  noted in  few countries  such as
Malaysia, Vietnam, and Thailand, which were 1.90, 2.04, and 1.58, respectively
in 2017.
Key players operating in the reproductive hormone market include, AbbVie Inc.,
Allergan plc, Pfizer Inc., Novo Nordisk A/S, Endo Pharmaceuticals Inc., and few
others.
The reproductive hormone market  is  segmented on the basis  of  by hormone
type, end user, and region.
Get the main link:-  https://www.coherentmarketinsights.com/ongoing-insight/reproductive-hormone-
market-3185 
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]
Visit our news Website: http://www.coherentchronicle.com/